

Bangkok Dusit Medical Services Public Company Limited
and its subsidiaries
Review report and interim financial information
For the three-month period ended 31 March 2023

Independent Auditor's Report on Review of Interim Financial Information

To the Shareholders of Bangkok Dusit Medical Services Public Company Limited

I have reviewed the accompanying consolidated statement of financial position of Bangkok Dusit Medical Services Public Company Limited and its subsidiaries ("the Group") as at 31 March 2023, and the related consolidated statements of income, comprehensive income, changes in shareholders' equity and cash flows for the three-month period then ended, as well as the condensed notes to the interim consolidated financial statements. I have also reviewed the separate financial information of Bangkok Dusit Medical Services Public Company Limited for the same period (collectively "interim financial information"). Management is responsible for the preparation and presentation of this interim financial information in accordance with Thai Accounting Standard No. 34 Interim Financial Reporting. My responsibility is to express a conclusion on this interim financial information based on my review.

Scope of Review

I conducted my review in accordance with Thai Standard on Review Engagements 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Thai Standards on Auditing and consequently does not enable me to obtain assurance that I would become aware of all significant matters that might be identified in an audit. Accordingly, I do not express an audit opinion.

Conclusion

Based on my review, nothing has come to my attention that causes me to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard No. 34 Interim Financial Reporting.

Wichart Lokatekrawee

Certified Public Accountant (Thailand) No. 4451

EY Office Limited

Bangkok: 11 May 2023

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries

Statement of financial position

As at 31 March 2023

(Unit: Thousand Baht)

	Note	Consolidated financial statements		Separate financial statements	
		As at	As at	As at	As at
		31 March 2023	31 December 2022	31 March 2023	31 December 2022
		(Unaudited but reviewed)	(Audited)	(Unaudited but reviewed)	(Audited)
Assets					
Current assets					
Cash and cash equivalents		16,485,101	12,668,014	5,898,568	4,095,282
Trade and other receivables	2, 3	10,527,809	10,484,453	1,966,683	1,538,508
Short-term loans to subsidiaries	3	-	-	2,459,694	2,567,990
Dividend receivables - related parties	3	14,163	-	4,170,068	-
Inventories		2,019,480	2,211,278	116,376	129,900
Current portion of					
- Other non-current financial assets	4	15,000	16,000	-	-
- Long-term loans to subsidiaries	3	-	-	90,000	90,000
Other current financial assets		1,299,401	2,303,564	86	86
Other current assets		57,803	115,768	29	6,991
Total current assets		30,418,757	27,799,077	14,701,504	8,428,757
Non-current assets					
Restricted financial institution deposits		4,606	4,609	-	-
Other non-current financial assets	4	1,062,477	1,018,107	861,023	813,570
Investments in associates	5	983,520	963,470	69,952	69,952
Investments in subsidiaries	6	-	-	63,242,163	63,241,874
Long-term loans to subsidiaries	3	-	-	408,320	432,076
Investment properties		380,258	380,258	726,359	726,359
Property, premises and equipment	7	82,001,813	81,859,991	13,539,262	13,623,611
Right-of-use assets	8	9,714,803	9,668,432	813,499	842,084
Goodwill		17,538,869	17,538,869	-	-
Intangible assets		1,689,942	1,621,177	716,420	742,525
Deferred tax assets		83,167	77,676	-	-
Other non-current assets		630,455	611,195	49,321	49,345
Total non-current assets		114,089,910	113,743,784	80,426,319	80,541,396
Total assets		144,508,667	141,542,861	95,127,823	88,970,153

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries

Statement of financial position (continued)

As at 31 March 2023

(Unit: Thousand Baht)

	Note	Consolidated financial statements		Separate financial statements	
		As at	As at	As at	As at
		31 March 2023	31 December 2022	31 March 2023	31 December 2022
		(Unaudited but reviewed)	(Audited)	(Unaudited but reviewed)	(Audited)
Liabilities and shareholders' equity					
Current liabilities					
Short-term loan from financial institutions	9	3,000,000	500,000	3,000,000	500,000
Trade and other payables	3	5,312,574	6,175,970	926,348	1,102,371
Accrued expenses	3	6,493,935	5,425,639	1,291,702	1,042,579
Current portion of long-term liabilities					
- Liabilities under lease agreements		856,347	880,375	196,797	126,295
- Debentures	10	2,499,774	4,999,842	2,499,774	4,999,842
Short-term loans from non-related parties		-	32,000	-	-
Short-term loans from subsidiaries	3	-	-	17,665,678	15,004,852
Income tax payable		2,166,553	1,471,565	270,451	138,773
Deferred income - membership due within one year		184,665	183,249	100,581	99,381
Other current liabilities		1,426,966	947,674	149,113	249,916
Total current liabilities		21,940,814	20,616,314	26,100,444	23,264,009
Non-current liabilities					
Long-term loan from financial institution		4,000,000	4,000,000	4,000,000	4,000,000
Liabilities under lease agreements		6,804,259	6,683,842	516,559	604,417
Debentures	10	4,998,237	6,497,815	4,998,237	6,497,815
Provision for life long medical care programs		1,749,243	1,666,045	1,512,017	1,431,300
Provision for employee benefits		3,955,664	3,886,455	1,243,548	1,223,284
Deferred income - membership		509,537	486,095	131,765	109,287
Deferred tax liabilities		3,889,508	3,920,406	325,958	341,142
Other non-current liabilities		80,378	73,100	32,791	32,650
Total non-current liabilities		25,986,826	27,213,758	12,760,875	14,239,895
Total liabilities		47,927,640	47,830,072	38,861,319	37,503,904

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries

Statement of financial position (continued)

As at 31 March 2023

(Unit: Thousand Baht)

	<u>Consolidated financial statements</u>		<u>Separate financial statements</u>	
	As at	As at	As at	As at
	<u>31 March 2023</u>	<u>31 December 2022</u>	<u>31 March 2023</u>	<u>31 December 2022</u>
	(Unaudited but reviewed)	(Audited)	(Unaudited but reviewed)	(Audited)
Liabilities and shareholders' equity (continued)				
Shareholders' equity				
Share capital				
Registered				
17,582,235,672 ordinary shares of Baht 0.1 each	<u>1,758,224</u>	<u>1,758,224</u>	<u>1,758,224</u>	<u>1,758,224</u>
Issued and fully paid-up				
15,892,001,895 ordinary shares of Baht 0.1 each	1,589,200	1,589,200	1,589,200	1,589,200
Premium on ordinary shares	30,166,103	30,166,103	30,103,179	30,103,179
Difference from shareholding restructure	305,000	305,000	-	-
Surplus investment over book value of subsidiaries	(3,956,165)	(3,954,357)	-	-
Retained earnings				
Appropriated - statutory reserve	175,822	175,822	175,822	175,822
Unappropriated	51,256,218	47,774,161	21,494,773	16,716,095
Other components of shareholders' equity	<u>13,830,346</u>	<u>13,823,325</u>	<u>2,903,530</u>	<u>2,881,953</u>
Equity attributable to owners of the Company	93,366,524	89,879,254	56,266,504	51,466,249
Non - controlling interests of the subsidiaries	<u>3,214,503</u>	<u>3,833,535</u>	-	-
Total shareholders' equity	<u>96,581,027</u>	<u>93,712,789</u>	<u>56,266,504</u>	<u>51,466,249</u>
Total liabilities and shareholders' equity	<u>144,508,667</u>	<u>141,542,861</u>	<u>95,127,823</u>	<u>88,970,153</u>
	-	-	-	-

The accompanying notes are an integral part of the financial statements.

Directors

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries**Income statement****For the three-month period ended 31 March 2023**

(Unit: Thousand Baht except earnings per share expressed in Baht)

		Consolidated financial statements		Separate financial statements	
	Note	2023	2022	2023	2022
Revenues					
Revenues from hospital operations		23,084,106	22,164,901	4,081,488	3,273,012
Revenue from sales of goods		925,739	821,033	-	-
Other income					
Dividend income		12,255	-	4,182,323	2,104,186
Others		302,944	172,999	400,458	359,413
Total other income		315,199	172,999	4,582,781	2,463,599
Total revenues		24,325,044	23,158,933	8,664,269	5,736,611
Expenses					
Cost of hospital operations and goods sold		15,121,705	14,450,836	2,531,486	2,197,456
Administrative expenses		4,632,962	4,024,832	1,092,089	963,688
Total expenses		19,754,667	18,475,668	3,623,575	3,161,144
Profit from operating activities		4,570,377	4,683,265	5,040,694	2,575,467
Share of income from investments in associates	5	34,213	8,827	-	-
Finance income		25,756	12,566	39,816	35,989
Finance costs		(164,005)	(158,272)	(162,560)	(140,558)
Profit before income tax expense		4,466,341	4,546,386	4,917,950	2,470,898
Income tax expense		(879,776)	(902,573)	(139,272)	(68,930)
Profit for the periods		3,586,565	3,643,813	4,778,678	2,401,968
Profit attributable to:					
Owners of the Company		3,470,112	3,443,034	4,778,678	2,401,968
Non-controlling interests of the subsidiaries		116,453	200,779		
		3,586,565	3,643,813		
Basic earnings per share					
Profit attributable to owners of the Company	11	0.22	0.22	0.30	0.15
Weighted average number of ordinary shares (shares)		15,892,001,895	15,892,001,895	15,892,001,895	15,892,001,895

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries**Statement of comprehensive income****For the three-month period ended 31 March 2023**

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2023	2022	2023	2022
Profits for the periods	3,586,565	3,643,813	4,778,678	2,401,968
Other comprehensive income:				
<i>Other comprehensive income to be reclassified to profit or loss in subsequent periods</i>				
Exchange differences on translation of financial statements in foreign currencies	(46,880)	(6,130)	-	-
Other comprehensive income to be reclassified to profit or loss in subsequent periods - net of income tax	(46,880)	(6,130)	-	-
<i>Other comprehensive income not to be reclassified to profit or loss in subsequent periods</i>				
Gain on fair value adjustments of investments - net of income tax	52,101	46,012	21,577	6,604
Other comprehensive income not to be reclassified to profit or loss in subsequent periods - net of income tax	52,101	46,012	21,577	6,604
Other comprehensive income for the periods	5,221	39,882	21,577	6,604
Total comprehensive income for the periods	3,591,786	3,683,695	4,800,255	2,408,572
Total comprehensive income attributable to:				
Equity holders of the Company	3,489,078	3,472,522	4,800,255	2,408,572
Non-controlling interests of the subsidiaries	102,708	211,173		
	3,591,786	3,683,695		

The accompanying notes are an integral part of the financial statements.

Statement of changes in shareholders' equity

For the three-month period ended 31 March 2023

(Unit: Thousand Baht)

Consolidated financial statements													
Equity attributable to owners of the Company													
Other components of shareholders' equity													
Other comprehensive income													
Exchange differences on translation of financial statements in foreign currency													
Total other components of shareholders' equity													
Total equity attributable to owners of the Company													
Equity attributable to non-controlling interest of the subsidiaries													
Total shareholders' equity													
Issued and paid-up share capital	Premium on ordinary shares	Difference from shareholding restructure	Surplus of investment over book value of subsidiaries	Appropriated-statutory reserve	Unappropriated	Accumulated fair value adjustment of investments	Revaluation surplus on land	foreign currency	equity	the Company	subsidaries	equity	
Balance as at 1 January 2022	1,589,200	30,166,103	305,000	(2,698,384)	175,822	42,772,863	133,102	11,386,126	15,361	11,534,589	83,845,193	3,919,739	87,764,932
Profit for the period	-	-	-	-	-	3,443,034	-	-	-	-	3,443,034	200,779	3,643,813
Other comprehensive income for the period	-	-	-	-	-	-	36,893	-	(7,405)	29,488	29,488	10,394	39,882
Total comprehensive income for the period	-	-	-	-	-	3,443,034	36,893	-	(7,405)	29,488	3,472,522	211,173	3,683,695
Change in non-controlling interests of subsidiaries													
- Additional purchase of investment in a subsidiary	-	-	-	136	-	-	-	-	-	-	136	(492)	(356)
- Dividend paid of subsidiaries	-	-	-	-	-	-	-	-	-	-	-	(152,768)	(152,768)
Balance as at 31 March 2022	1,589,200	30,166,103	305,000	(2,698,248)	175,822	46,215,897	169,995	11,386,126	7,956	11,564,077	87,317,851	3,977,652	91,295,503

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries

(Unaudited but reviewed)

Statement of changes in shareholders' equity (continued)

For the three-month period ended 31 March 2023

(Unit: Thousand Baht)

Consolidated financial statements												
Equity attributable to owners of the Company												
Other components of shareholders' equity												
Other comprehensive income												
Exchange differences on translation of financial statements in foreign currency												
Total other components of shareholders' equity												
Total equity attributable to owners of the Company												
Equity attributable to non-controlling interest of the subsidiaries												
Total shareholders' equity												
Issued and paid-up share capital	Premium on ordinary shares	Difference from shareholding restructure	Surplus of investment over book value of subsidiaries	Appropriated-statutory reserve	Unappropriated	Accumulated fair value adjustment of investments	Revaluation surplus on land	Exchange differences on translation of financial statements in foreign currency	Total other components of shareholders' equity	Total equity attributable to owners of the Company	Equity attributable to non-controlling interest of the subsidiaries	Total shareholders' equity
Balance as at 1 January 2023	1,589,200	30,166,103	305,000	(3,954,357)	175,822	47,774,161	179,044	13,571,142	73,139	13,823,325	89,879,254	93,712,789
Profit for the period	-	-	-	-	-	3,470,112	-	-	-	3,470,112	116,453	3,586,565
Other comprehensive income for the period	-	-	-	-	-	-	52,000	-	(33,034)	18,966	18,966	5,221
Total comprehensive income for the period	-	-	-	-	-	3,470,112	52,000	-	(33,034)	18,966	102,708	3,591,786
Transfer accumulated fair value adjustment of investments to retained earnings due to sales of investments	-	-	-	-	-	11,945	(11,945)	-	-	(11,945)	-	-
Change in non-controlling interests of subsidiaries												
- Additional purchase of investment in subsidiaries	-	-	-	(1,808)	-	-	-	-	-	(1,808)	(4,232)	(6,040)
- Dividend paid of subsidiaries	-	-	-	-	-	-	-	-	-	-	(717,508)	(717,508)
Balance as at 31 March 2023	1,589,200	30,166,103	305,000	(3,956,165)	175,822	51,256,218	219,099	13,571,142	40,105	13,830,346	3,214,503	96,581,027

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries

(Unaudited but reviewed)

Statement of changes in shareholders' equity (continued)

For the three-month period ended 31 March 2023

(Unit: Thousand Baht)

Separate financial statements							
				Other components of shareholders' equity			
				Other comprehensive income			
Retained earnings				Accumulated		Total other	
Issued and		Appropriated-		fair value	Revaluation	components of	Total
paid-up	Premium on	statutory		adjustment	surplus on	shareholders'	shareholders'
share capital	ordinary shares	reserve	Unappropriated	of investments	land	equity	equity
Balance as at 1 January 2022	1,589,200	30,103,179	175,822	17,370,383	110,354	2,083,944	51,432,882
Profit for the period	-	-	2,401,968	-	-	-	2,401,968
Other comprehensive income for the period	-	-	-	6,604	-	6,604	6,604
Total comprehensive income for the period	-	-	2,401,968	6,604	-	6,604	2,408,572
Balance as at 31 March 2022	<u>1,589,200</u>	<u>30,103,179</u>	<u>175,822</u>	<u>19,772,351</u>	<u>116,958</u>	<u>2,083,944</u>	<u>53,841,454</u>
Balance as at 1 January 2023	1,589,200	30,103,179	175,822	16,716,095	182,827	2,699,126	51,466,249
Profit for the period	-	-	4,778,678	-	-	-	4,778,678
Other comprehensive income for the period	-	-	-	21,577	-	21,577	21,577
Total comprehensive income for the period	-	-	4,778,678	21,577	-	21,577	4,800,255
Balance as at 31 March 2023	<u>1,589,200</u>	<u>30,103,179</u>	<u>175,822</u>	<u>21,494,773</u>	<u>204,404</u>	<u>2,903,530</u>	<u>56,266,504</u>

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries**Statement of cash flows****For the three-month period ended 31 March 2023**

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2023	2022	2023	2022
Cash flows from operating activities				
Profit before income tax expense	4,466,341	4,546,386	4,917,950	2,470,898
Adjustments to reconcile profit before income tax expense to net cash provided by (paid from) operating activities:				
Depreciation and amortisation	1,429,119	1,490,131	305,732	330,430
Write-off of assets	2,464	379	2,398	1
Gain from lease agreement amendment	(5,127)	(687)	-	(80)
Loss (reversal) on impairment of assets	285	-	-	(244)
Loss on withholding tax diminution and written-off	231	4,633	-	-
Bad debt and expected credit losses	61,022	35,508	17,858	15,698
Allowance (reversal) to reduce cost to net realisable value - inventory	6,414	(225)	126	400
Amortisation of deferred income - membership	(63,881)	(68,926)	(31,148)	(29,572)
(Gain) loss on fair value measurement of other financial assets	(21,511)	37,308	(20,483)	37,644
Share of income from investments in associates	(34,213)	(8,827)	-	-
Amortisation of expense for debentures	354	456	354	456
(Gain) loss on disposal of property, premises and equipment	(559)	1,778	(641)	(107)
Loss on foreign exchange	1,713	403	1,713	403
Provision for life long medical care programs	70,638	65,145	68,035	62,947
Provision for employee benefit expenses	91,383	93,735	23,094	26,373
Annual leave expense	37,841	38,121	8,356	7,524
Finance income	(25,756)	(12,566)	(39,816)	(35,989)
Dividend income	(12,255)	-	(4,182,323)	(2,104,186)
Finance cost	164,005	158,272	162,560	140,558
Profit from operating activities before changes in operating assets and liabilities	6,168,508	6,381,024	1,233,765	923,154

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries**Statement of cash flows (continued)****For the three-month period ended 31 March 2023**

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2023	2022	2023	2022
Cash flows from operating activities (continued)				
Decrease (increase) in operating assets				
Trade and other receivables	(92,056)	(1,921,702)	(433,686)	(253,082)
Inventories	185,384	66,130	13,398	19,161
Other current assets	57,965	314,094	6,962	50,195
Other non-current assets	(52,725)	9,493	27	144
Increase (decrease) in operating liabilities				
Trade and other payables	(790,452)	(16,512)	(99,162)	8,104
Accrued expenses	1,048,695	1,146,896	254,773	193,342
Deferred income - membership	88,739	58,666	54,825	30,323
Other current liabilities	(231,504)	(456,681)	(95,956)	(121,713)
Provision for life long medical care programs	12,560	(13,146)	12,682	(13,043)
Provision for employee benefits	(22,175)	(23,596)	(2,830)	(2,292)
Other non-current liabilities	7,277	5,071	140	36
Cash flow provided by operating activities	6,380,216	5,549,737	944,938	834,329
Cash received from finance income	14,460	3,614	27,469	27,217
Cash paid for finance cost	(149,998)	(184,144)	(170,965)	(193,523)
Cash received from tax refund	14,174	21,215	-	-
Cash paid for income tax expense	(253,948)	(243,678)	(28,172)	(27,372)
Net cash flow provided by operating activities	6,004,904	5,146,744	773,270	640,651

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries**Statement of cash flows (continued)****For the three-month period ended 31 March 2023**

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2023	2022	2023	2022
Cash flows from investing activities				
(Increase) decrease in other current financial assets	1,004,163	(878,853)	-	-
Decrease in restricted financial institution deposits	3	3	-	-
Cash received from dividend income	12,255	-	12,255	574,584
Cash paid for purchase of investments in subsidiaries	-	-	(289)	(356)
Cash received from capital returned from an associate	-	863	-	863
Cash paid for purchase of other non-current financial asset	(12,000)	-	-	-
Cash received from disposal of other non-current financial asset	54,238	-	-	-
Decrease in short-term loans to subsidiaries	-	-	107,839	308,954
Cash received from long-term loans to subsidiaries	-	-	22,500	31,600
Cash received from disposal of property, premises and equipment	4,817	3,627	710	630
Cash paid for purchase of property, premises and equipment	(1,425,132)	(1,123,932)	(175,642)	(74,247)
Cash paid for purchase of intangible assets	(146,719)	(146,607)	(62,509)	(63,089)
Net cash flow provided by (used in) investing activities	(508,375)	(2,144,899)	(95,136)	778,939

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries**Statement of cash flows (continued)****For the three-month period ended 31 March 2023**

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2023	2022	2023	2022
Cash flows from financing activities				
Decrease in short-term loans from non-related parties	(32,000)	(9,500)	-	-
Increase in short-term loans from subsidiaries	-	-	2,660,826	2,337,486
Increase in bank overdraft and short-term loans from financial institutions	2,500,000	-	2,500,000	-
Cash paid for debentures redemption	(4,000,000)	(2,500,000)	(4,000,000)	(2,500,000)
Repayments of liabilities under lease agreements	(134,691)	(101,155)	(30,826)	(146,777)
Cash paid for purchase of investment in subsidiaries from non - controlling interests	(6,040)	(356)	-	-
Dividend paid	(4,848)	(84)	(4,848)	(84)
Dividend paid by subsidiaries to non-controlling interests	(1,863)	(25,113)	-	-
Net cash flow provided by (used in) financing activities	(1,679,442)	(2,636,208)	1,125,152	(309,375)
Net increase in cash and cash equivalents	3,817,087	365,637	1,803,286	1,110,215
Cash and cash equivalents at beginning of periods	12,668,014	10,933,656	4,095,282	7,467,193
Cash and cash equivalents at end of periods	16,485,101	11,299,293	5,898,568	8,577,408

Supplemental cash flows information

Non-cash items

Increase in right-of-use assets	100,687	58,900	7,404	5,218
Increase (decrease) in accounts payable - property, premises, equipment, intangible assets and retention	(72,945)	56,212	(76,861)	(10,373)
Increase in dividend receivable	14,163	8,498	4,170,068	1,529,602
Increase (decrease) in dividend payable	710,797	127,571	(4,848)	(84)

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries
Notes to consolidated interim financial statements
For the three-month periods ended 31 March 2023

1. General information

1.1 Basis for the preparation of interim financial statements

These interim financial statements are prepared in accordance with Thai Accounting Standard 34 “Interim Financial Reporting”, with the Company choosing to present condensed interim financial statements. However, the Company has presented the statements of financial position, income, comprehensive income, changes in shareholders’ equity, and cash flows in the same format as that used for the annual financial statements.

The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events and circumstances so as not to duplicate information previously reported. These interim financial statements should therefore be read in conjunction with the latest annual financial statements.

The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the Thai language interim financial statements.

1.2 Basis of consolidation

These interim consolidated financial statements include the financial statements of Bangkok Dusit Medical Services Public Company Limited and its subsidiaries (“the Group”) and have been prepared on the same basis as that applied for the consolidated financial statements for the year ended 31 December 2022. There have been changes in the structure of the subsidiaries during the current period as discussed in Note 6 to the financial statements.

1.3 Significant accounting policies

The interim financial statements are prepared using the same accounting policies and methods of computation as were used for the financial statements for the year ended 31 December 2022.

The revised financial reporting standards which are effective for fiscal years beginning on or after 1 January 2023, do not have any significant impact on the Group’s financial statements.

2. Trade and other receivables

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	31 March 2023	31 December 2022	31 March 2023	31 December 2022
Trade receivables - related parties	5,406	6,737	34,641	28,981
Trade receivables - unrelated parties - net	9,876,257	9,969,352	1,565,384	1,247,674
Other receivables - related parties	2,326	2,368	260,815	205,971
Other receivables - unrelated parties - net	319,718	268,037	28,858	22,751
Prepaid expenses	324,102	237,959	76,985	33,131
Total trade and other receivables - net	<u>10,527,809</u>	<u>10,484,453</u>	<u>1,966,683</u>	<u>1,538,508</u>

As at 31 March 2023 and 31 December 2022, the aging analysis of the outstanding trade receivables is as follows:

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	31 March 2023	31 December 2022	31 March 2023	31 December 2022
<u>Related parties</u>				
Undue	2,731	3,888	23,767	20,853
Not over than 3 months	2,050	2,667	10,689	8,007
3 - 6 months	624	181	149	47
6 -12 months	-	1	36	74
Over 12 months	1	-	-	-
Total trade receivables - related parties	<u>5,406</u>	<u>6,737</u>	<u>34,641</u>	<u>28,981</u>
<u>Unrelated parties</u>				
Undue	4,831,801	4,643,746	706,142	574,893
Not over than 3 months	3,327,406	3,576,060	614,475	550,217
3 - 6 months	944,437	1,034,658	230,801	104,362
6 - 12 months	682,659	700,561	39,063	59,627
Over 12 months	703,935	567,244	126,194	92,009
Total trade receivables - unrelated parties	<u>10,490,238</u>	<u>10,522,269</u>	<u>1,716,675</u>	<u>1,381,108</u>
Less: Allowance for expected credit losses	<u>(613,981)</u>	<u>(552,917)</u>	<u>(151,291)</u>	<u>(133,434)</u>
Total trade receivables - unrelated parties - net	<u>9,876,257</u>	<u>9,969,352</u>	<u>1,565,384</u>	<u>1,247,674</u>
Total trade receivables - net	<u><u>9,881,663</u></u>	<u><u>9,976,089</u></u>	<u><u>1,600,025</u></u>	<u><u>1,276,655</u></u>

3. Related party transactions

During the periods, the Group had significant business transactions with individuals or related parties, which have been concluded on commercial terms and bases agreed upon between the Company and those related parties. There were no significant changes in the transfer pricing policy of transactions with related parties during the current period.

The significant intercompany transactions are as follows:

	(Unit: Million Baht)			
	For the three-month periods ended 31 March			
	Consolidated		Separate	
	financial statements		financial statements	
	2023	2022	2023	2022
<u>Associates</u>				
Revenue from hospital operations and laboratory services	0.1	2.2	-	-
Revenues from sales and other income	1.1	0.4	-	-
Costs of goods and services	5.3	3.4	0.3	0.1
<u>Subsidiaries</u>				
Revenue from hospital operations and laboratory services	-	-	54.3	44.6
Consulting and management fee income	-	-	300.9	287.4
Finance income	-	-	28.9	26.8
Dividend income	-	-	4,170.0	2,104.2
Other income	-	-	69.8	28.3
Costs of goods and services	-	-	334.6	246.0
Consulting and management fee expenses	-	-	64.7	60.5
Other expenses	-	-	12.0	7.9
Finance costs	-	-	25.8	10.3
<u>Individuals or related companies</u>				
Revenue from hospital operations and laboratory services	1.3	13.4	0.9	5.2
Other income	5.1	3.4	3.9	2.3
Costs of goods and services	38.7	37.4	35.2	35.6
Consulting and management fee expenses	0.8	0.8	-	-
Other expenses	26.6	15.2	15.9	9.9

The outstanding balances of the above transactions as at 31 March 2023 and 31 December 2022 have been separately shown in the statement of financial position as follows:

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	31 March	31 December	31 March	31 December
	2023	2022	2023	2022
<u>Trade receivables - related parties (Note 2)</u>				
Associates	1,338	1,921	-	-
Subsidiaries	-	-	34,051	28,596
Related companies	4,068	4,816	590	385
Total trade receivables - related parties	5,406	6,737	34,641	28,981
<u>Other receivables - related parties (Note 2)</u>				
Consulting and management fee receivable				
Subsidiaries	-	-	120,342	100,116
Total	-	-	120,342	100,116
Accrued interest income and others				
Subsidiaries	-	-	139,505	104,876
Related companies	2,326	2,368	968	979
Total	2,326	2,368	140,473	105,855
Total other receivables - related parties	2,326	2,368	260,815	205,971
<u>Dividend Receivable- related parties</u>				
An associate	14,163	-	-	-
Subsidiaries	-	-	4,170,068	-
Total	14,163	-	4,170,068	-
<u>Other non-current assets - related parties</u>				
Subsidiaries	-	-	9,419	9,439
Related companies	8,704	4,101	-	-
Total other non-current assets - related parties	8,704	4,101	9,419	9,439

(Unaudited but reviewed)

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	31 March	31 December	31 March	31 December
	2023	2022	2023	2022
<u>Trade payables - related parties</u>				
Associates	5,235	4,211	328	318
Subsidiaries	-	-	104,352	91,722
Related companies	10,180	10,768	8,392	9,090
Total trade payables - related parties	15,415	14,979	113,072	101,130
<u>Other payables - related parties</u>				
Subsidiaries	-	-	96,408	124,288
Related companies	6,450	2,785	5,912	4,439
Total other payables - related parties	6,450	2,785	102,320	128,727
<u>Accrued interest expenses - related parties</u>				
Subsidiaries	-	-	10,270	5,949
Total accrued interest expenses - related parties	-	-	10,270	5,949
<u>Liabilities under lease agreements - related parties</u>				
A subsidiary	-	-	206,795	206,395
Related companies	61,320	32,898	15,327	11,945
Total liabilities under lease agreements - related parties	61,320	32,898	222,122	218,340
<u>Other non-current liabilities - related parties</u>				
Subsidiaries	-	-	12,897	12,884
Related companies	1,229	1,229	942	942
Total other non-current liabilities - related parties	1,229	1,229	13,839	13,826

Movement of loans to and loans from subsidiaries during the period are summarised as follows:

(Unit: Thousand Baht)

	Separate financial statements			
	31 December		31 March	
	2022	Increase	Decrease	2023
Short-term loans to subsidiaries	2,567,990	241,616	(349,912)	2,459,694
Long-term loans to subsidiaries	522,076	-	(23,756)	498,320
Short-term loans from subsidiaries	15,004,852	2,889,286	(228,460)	17,665,678

Short-term and long-term loans to subsidiaries and short-term loans from subsidiaries

The Company has entered into agreements to provide short-term loans and long-term loans with terms of 3 - 8 years to subsidiaries. The loans bear interest at MLR minus fixed rate per annum and LIBOR plus fixed rate per annum and fixed rate as stipulated in the agreement. The interest is payable on a monthly basis while principal is repayable on the basis as stipulated in the agreements.

The Company has entered into short-term loans agreements from its subsidiaries. The loans bear interest at fixed deposit rate. The interest is payable on a monthly basis while principal is repayable on the basis as stipulated in the agreements.

Guarantee obligations with subsidiaries

As at 31 March 2023, the Company has guaranteed overdraft facility amounting to USD 2 million (31 December 2022: USD 2 million) for overseas subsidiaries.

Directors and management's benefits

During the periods, directors and management's benefit of the Group are as below.

(Unit: Million Baht)

	For the three-month periods ended 31 March			
	Consolidated		Separate	
	financial statements		financial statements	
	2023	2022	2023	2022
Short-term employee benefits	48.0	37.6	31.1	28.8
Post-employment benefits	0.4	1.3	0.4	1.3
Total	48.4	38.9	31.5	30.1

Apart from short-term employee benefits, executive management also receives medical benefits according to the Company policy, the same with employees of the Company. External Directors, referring to directors who are not an employee or management according to the employment agreement, receive a medical fee budget of Baht 3 million per person per year to be used only for medical fees at Bangkok Hospital and hospitals within the Group.

4. Other non-current financial assets

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	31 March	31 December	31 March	31 December
	2023	2022	2023	2022
Investments in equity instruments (measured at fair value through other comprehensive income)	997,118	970,229	823,641	796,670
Investments in debt instruments (measured at amortised cost)	42,977	46,978	-	-
Derivatives assets - Interest rate swap contract (Note 10 and 14)	37,382	16,900	37,382	16,900
Total	1,077,477	1,034,107	861,023	813,570
Less: Current portion of investments in debt instruments	(15,000)	(16,000)	-	-
Total other non-current financial assets	1,062,477	1,018,107	861,023	813,570

5. Investments in associates

Details of share of profit (loss) from investments in associates

Company's name	(Unit: Thousand Baht)	
	Consolidated	
	financial statements	
	For the three-month periods ended	
	31 March 2023	31 March 2022
<u>Associates held by the Company</u>		
Cool & Joy Co., Ltd.	-	(7)
Udon Patana (1994) Co., Ltd. (held by the Company at 15.26% and indirectly held by a subsidiary at 9.86%)	21,236	(7,231)
<u>Associates held by the subsidiaries</u>		
General Hospital Products Public Co., Ltd.	12,977	16,065
Total	34,213	8,827

6. Investments in subsidiaries

During the period, the movements of investments in subsidiaries are as follows:

Additional investments in subsidiaries

Company's name	Additional investments (Million Baht)	% Shareholding of the Group	
		31 March 2023	31 December 2022
Held by the Company			
Prasit Patana Public Co., Ltd.	0.3	98.63	98.63
Held by the subsidiaries			
Digital Health Venture Co., Ltd	100.0	100.00	100.00
Sriracha Nakorn General Hospital Public Co., Ltd.	5.8	77.51	77.44

Digital Health Venture Co., Ltd.

On 1 February 2023, the Board of Director Meeting No. 1/2023 of Digital Health Venture Co., Ltd. ,100% subsidiary of a subsidiary, call-up share capital of Baht 33.33 per share, totaling Baht 100 million. The subsidiary had already paid for the call-up share capital on 15 February 2023.

7. Property, premises and equipment

Movement of the property, premises and equipment during the three-month period ended 31 March 2023 are summarised below.

	(Unit: Thousand Baht)	
	Consolidated financial statements	Separate financial statements
Net book value as at 31 December 2022	81,859,991	13,623,611
Purchase	1,383,740	143,335
Transfer in	25,770	60
Disposals and write-off	(4,400)	(69)
Depreciation for the period	(1,240,360)	(227,675)
Translation adjustment	(22,928)	-
Net book value as at 31 March 2023	<u>82,001,813</u>	<u>13,539,262</u>

8. Right-of-use assets

Movements of right-of-use assets during the three-month period ended 31 March 2023 are summarised below.

	(Unit: Thousand Baht)	
	Consolidated financial statements	Separate financial statements
Net book value as at 31 December 2022	9,668,432	842,084
Increase	100,687	7,404
Lease modification	75,343	-
Transfer out	(26,506)	-
Decrease	(2,801)	-
Depreciation for the period	(100,352)	(35,989)
Net book value as at 31 March 2023	<u>9,714,803</u>	<u>813,499</u>

9. Short-term loan from financial institutions

9.1 Short-term loan from financial institution

As at 31 March 2023, the Company had outstanding balances of short-term loan from financial institution of Baht 3,000 million (31 December 2022: 500 million). The loan carries interest at a fixed rate payable in accordance with conditions as stipulated in the agreement. The short-term loan principal is due in June 2023 as specified in the agreement.

9.2 Undrawn down credit facilities

As at 31 March 2023, undrawn down credit facilities from financial institutions are as follows;

	Consolidated financial statements	Separate financial statements
Thai Baht	Baht 18,964 million	Baht 18,669 million
US Dollar	USD 2 million	-

10. Debentures

Movements of debentures net from debenture expenses and amortisation of expenses during the three-month period ended 31 March 2023 are summarised below.

	(Unit: Thousand Baht)
	Consolidated/ Separate financial statements
Balance as at 31 December 2022	11,497,657
Amortisation of debenture expenses during the period	354
Less: Redemption of debentures during the period	(4,000,000)
Balance as at 31 March 2023	7,498,011
Less: Current portion of debentures	(2,499,774)
Debentures	4,998,237

The Company has entered into the Interest Rate Swap contract with a financial institution for BDMS256A by converting the fixed coupon rate per annum to the floating interest rate plus spread per annum.

Debenture agreement contains certain covenants which the Company must comply with such as financial ratios, payment of dividend, assets dispositions, etc.

11. Earnings per share

Basic earnings per share is determined by dividing profit for the period attributable to owner of the Company (excluding other comprehensive income) by the weighted average number of ordinary shares in issue during the period.

12. Commitments and contingent liabilities

(Unit: Million Baht)

	As at 31 March 2023				
	Consolidated			Separate	
	financial statements			financial statements	
	Within 1 year	1 - 5 years	Over 5 years	Within 1 year	1 - 5 years
Contractual commitments					
- the office equipment rental and other service contracts	518	462	31	172	2
- the medical equipment maintenance contracts	293	144	4	-	-
- the building construction and improvement contracts	1,260	-	-	110	-
Total	2,071	606	35	282	2

Contingent liabilities

As at 31 March 2023, the Group had outstanding bank guarantees of approximately Baht 466 million and the Company's of Baht 42 million issued by the bank on behalf of the Group in respect of certain performance bonds as required in the normal course of business, such as facility usage and contractual performance.

13. Segment information

Operating segment information is reported in a manner consistent with the internal reports that are regularly reviewed by the chief operating decision maker in order to make decisions about the allocation of resources to the segment and assess its performance. The chief operating decision maker has been identified as the executive committee.

The Group has two reportable segments that are hospital operations and other businesses that support hospital business such as medical laboratories, production and distribution of pharmaceutical products/medical equipment/saline, pharmacies, assets management for healthcare business, accounting services, technology and information services, training business and insurance broker. These two segments have similar economic characteristics. They both have common customer group, similar service provision methods and similar management.

In addition, the operations of the Group are carried on in the geographical areas of Thailand and overseas.

As hospital operation is the main business segment and the segment information that has been considered based on a quantitative basis is over 90 percent of the total population both operational and geographical areas. As a result, all of the revenues, operating profits and assets as reflected in these financial statements pertain to the aforementioned reportable operating segment and geographical areas.

For the three-month periods ended 31 March 2023 and 2022, the Group has no major customer with revenue of 10 percent or more of its revenues.

14. Financial instruments

14.1 Fair value of financial instruments

Since the majority of the Group financial instruments are classified as short-term or bear floating interest rates or fixed interest rates which are close to market rate, their fair value is not expected to be materially different from the amounts presented in the statement of financial position.

14.2 Fair value hierarchy

As at 31 March 2023, the Group had the financial assets and liabilities that were measured at fair value which using different levels of inputs as follows.

(Unit: Million Baht)				
As at 31 March 2023				
Consolidated Financial Statements				
	Level 1	Level 2	Level 3	Total
Financial assets measured at fair value				
Other current financial assets				
- Investments in mutual funds				
(measured at fair value through profit or loss)	-	512	-	512
Other non-current financial assets				
- Investments in equity instruments				
(measured at fair value through other comprehensive income)	797	-	200	997
- Derivatives liabilities - interest rate swap contract	-	37	-	37

(Unaudited but reviewed)

(Unit: Million Baht)

	As at 31 March 2023			
	Separate Financial Statements			
	Level 1	Level 2	Level 3	Total
Financial assets measured at fair value				
Other non-current financial assets				
- Investments in equity instruments				
(measured at fair value through other comprehensive income)	797	-	27	824
- Derivatives liabilities - interest rate swap contract	-	37	-	37

15. Event after the reporting period

On 7 April 2023, the 2023 Annual General Meeting of the Company's shareholders has approved a dividend payment for ordinary shares at Baht 0.60 per share, totaling of Baht 9,535.2 million. The interim dividend was paid at Baht 0.30 per share, totaling of Baht 4,767.6 million in September 2022. The remaining dividend payment was paid on 24 April 2023 at Baht 0.30 per share, totaling of Baht 4,767.6 million.

16. Approval of financial statements

These interim financial statements were authorised for issue by the Company's authorised directors on 11 May 2023.